Table 2.

Patient and treatment characteristics

Number of patientsP2
CRPRNRTotalCR vs. (PR + NR)(CR + PR) vs. NR
Total20324193
Patients
 Sex
  Male132029621.0<0.51
  Female7121231
 Age
  16–30354120.840.79
  31–457111432
  46–6010162147
  61–750022
 HLA
  A2152832750.530.61
  Non-A254918
 Stage
  M1a346130.550.56
  M1b3418
  M1c14243472
Treatments
 TBI, Gy
  051622430.0070.08
  2581225
  12108725
 Cells (×10−10)
  <3451019
  3.1–5.0341219
  5.1–7.0712726
  7.1–9.024410
  >947819
  Mean ± SEM6.5 ± 0.76.1 ± 0.55.5 ± 0.60.250.07
  % CD3CD8+86 ± 279 ± 474 ± 40.590.14
  % CD3CD4+10 ± 220 ± 424 ± 40.300.15
 Telomere length, kb6.7 ± 0.36.4 ± 0.25.1 ± 0.20.006<0.001
 CD8+CD27+ cells (×10−10)2.0 ± 0.31.5 ± 0.20.8 ± 0.10.001<0.001
 Persistence at 1 mo (%)30.2 ± 5.528 ± 5.910.5 ± 3.50.003<0.001
 IL-2 doses
  <51315
  5–815221956
  9–11472132
  Mean ± SEM7.1 ± 0.47.7 ± 0.58.8 ± 0.40.110.003

Abbreviations: M1a, skin, subcutaneous, or nodal metastases; M1b, lung; M1c all other visceral sites or elevated LDH levels.